Articles tagged with Tuberculosis
A new artificial intelligence-based method detects genetic markers of antibiotic resistance in bacteria, potentially leading to faster and more effective treatments. The method, called Group Association Model, uses machine learning to identify key mutations linked to drug resistance, reducing false positives and misdiagnoses.
The American College of Chest Physicians' CHEST Critical Care and CHEST Pulmonary journals have been indexed in Elsevier's Scopus database. This achievement is a testament to the high-quality research published in these journals, which provide open access content in pulmonary and critical care medicine.
A new molecular stool test has shown promise in detecting tuberculosis in adults living with HIV, particularly those with advanced AIDS. The test, known as Xpert MTB/Ultra, had a sensitivity of 23.7% and specificity of 94.0%, outperforming standard tests in some cases.
A new study found that reported tuberculosis diagnoses among incarcerated people in Europe and the Americas plummeted by up to 100% during the pandemic, despite consistent incarceration rates. This reduction was distinct from general population trends, highlighting the need for improved healthcare systems within prisons.
Researchers have identified several key genes and pathways involved in the bovine response to Mycobacterium bovis, the causative agent of tuberculosis in cattle. The study found that genetic variation affecting the initial proinflammatory immune response contributes to bTB susceptibility.
Childhood tuberculosis cases in the EU/EEA have increased by 26% over the past three years, with young children under 15 accounting for 4.3% of all TB cases. The rise in pediatric TB has raised concerns about incomplete treatment, drug-resistant TB, and further transmission.
A TB vaccination has been shown to boost the immune system of bladder cancer patients, reducing cancer recurrence rates by up to 75% in a small pilot study. The vaccine was well-tolerated with no side effects and showed promising results in improving patient outcomes.
Scientists have developed several innovative methods to combat tuberculosis, including a rapid fluorescence test that can diagnose the disease within minutes. Additionally, researchers have created sugar-coated nanoparticles that target infected macrophages, and encapsulated light-activated particles that inactivate bacteria with red l...
The European Centre for Disease Prevention and Control (ECDC) reports a rise in tuberculosis cases among children and adolescents in the EU/EEA, with a slight increase in the notification rate from 2.0 to 2.5 per 100,000 population. The highest proportion of paediatric TB was observed in children aged 1 to 4 years old.
CHEST MedCast offers over 400 videos and podcasts with personalized content recommendations, available on-demand and at any time from any device. The platform features an algorithm-based recommendation engine and up to 100 available CME credits/MOC points.
Researchers at Weill Cornell Medicine and MIT discovered a family of genes necessary for tuberculosis bacteria to survive airborne transmission. These genes help the bacteria adapt to changes in temperature, oxygen levels, and humidity, providing new targets for therapies that could treat infection and prevent spread.
Researchers have discovered a family of genes essential for tuberculosis survival during airborne transmission, providing new drug targets. The study sheds light on the bacterium's protective mechanisms, which could prevent infection spread and treat existing cases.
Kayunta Johnson-Winters, a UTA associate professor of chemistry and biochemistry, has been honored as an American Society for Biochemistry and Molecular Biology fellow. Her research on F420-dependent enzymes has expanded understanding of disease proteins and paved the way for potential treatments.
A new TB vaccine candidate has shown complete protection and a superior immune response in nonhuman primates compared to the existing BCG vaccine. The delta sigH vaccine resulted in a more balanced and effective elimination of the bacteria, with lower levels of inflammation and a different type of interferon triggered.
The collaboration aims to close gaps in early recognition and management of IPF by equipping healthcare providers, public health professionals, and patients with necessary resources. The organizations will employ designated activities to build a knowledge base, develop survey tools, and create educational and awareness assets.
Researchers at Weill Cornell Medicine develop two strains of mycobacteria with 'kill switches' that can be triggered to stop the bacteria after they activate an immune response. The new approach aims to accelerate vaccine development and overcome safety concerns.
The American College of Chest Physicians (CHEST) has developed an educational program and formal certification exam for nurse practitioners and physician assistants/associates in critical care. The program validates clinical expertise and demonstrates professional acumen, aiming to improve patient care.
A recent study found a significant negative correlation between neutrophil-to-lymphocyte ratio (NLR) and the risk of tuberculosis infection, especially in males and individuals with hypertension. NLR may serve as a biomarker for assessing TBI risk.
A new review highlights the shortcomings of existing methods for assessing socioeconomic status in TB studies, calling for more accurate and comprehensive measures. Adopting tools like the global multidimensional poverty index could lead to targeted interventions and stronger policy recommendations.
A groundbreaking study published in eBioMedicine has shown that a new mRNA vaccine is effective in boosting immunity against tuberculosis. The vaccine demonstrated potent immune responses in infected mice and improved long-term protection when combined with the BCG vaccine.
Researchers developed novel antibiotic BTZ-043 to target drug-resistant tuberculosis. The study showed that BTZ-043 effectively penetrates TB lesions and accumulates there in high concentrations, making it a promising treatment option for TB patients.
A new study by Wits University and NICD shows that conditional cash transfers and TB counselling improve treatment success rates and reduce loss to follow-up in South Africa. The intervention resulted in halving unsuccessful TB outcomes compared to standard care, bringing the country closer to its 90-90-90 TB targets.
Groundbreaking progress in TB vaccine development and therapeutic innovations offer hope to curb the disease's devastating impact, with multi-antigen vaccines and mRNA-based platforms showing promise.
A new study compares the allosteric regulation of Escherichia coli and Mycobacterium tuberculosis cAMP receptor proteins, revealing distinct regulatory mechanisms despite structural resemblance. The findings suggest species-specific control over bacterial gene regulation and have potential implications for drug development.
Researchers developed a next-generation technology, MycoBCP, using artificial intelligence to screen for antimicrobial compound candidates. This method has already vastly accelerated the team's TB research capabilities and helped identify optimal candidate compounds for drug development.
A major clinical trial has identified three new safe and effective regimens for treating drug-resistant tuberculosis, offering faster, safer, and more accessible care. The new treatments show promise in reducing treatment duration and side effects, making them a significant breakthrough in the fight against this infectious disease.
A new TB risk scoring tool has been developed to assess patients for potential TB infections, enabling accurate decisions on isolation precautions. The tool has been validated and is now in use at all MGB sites, positively impacting patient care and clinician workflows.
A clinical trial published in the New England Journal of Medicine showed that levofloxacin substantially reduced the risk of developing drug-resistant tuberculosis. The study found that levofloxacin reduced the risk of multidrug-resistant TB in adults and adolescents by 45 percent, and also significantly reduced the risk among family m...
A new self-destructing vaccine provides improved safety and protection against TB in macaque monkeys, outperforming the standard BCG vaccine. The 'kill switch' mechanism eliminates the risk of accidental infection, offering a safer vaccination option for immunocompromised individuals.
The report highlights a persistently high burden of TB in low- and middle-income countries, with 10.8 million new cases reported in 2023. It emphasizes the need for increased funding, improved diagnostics, and effective treatment regimens to combat drug-resistant TB.
A study found that over a quarter of TB drug-resistant strains result from patient-to-patient transmission, highlighting the need for improved surveillance and infection control. The emergence of highly drug-resistant TB poses a significant challenge to global health efforts.
A landmark study by Barcelona Institute for Global Health found that Brazil's Bolsa Família Program reduced TB cases and deaths among extreme poverty, indigenous groups, and improved healthcare access. The program's effects were stronger among the poorest and indigenous populations, with a 50-60% decrease in TB cases.
A new system can quickly identify emerging virus variants and provide information on their genetic changes, helping to understand why they spread differently in human populations. This enables the development of more effective vaccines and targeted treatments for diseases such as flu, COVID, and tuberculosis.
John Howington, MD, MBA, FCCP, is the new President of CHEST, succeeding Neil S. Freedman, who will be President-Elect in 2026. Dr. Howington has extensive leadership experience and has published over 49 research publications.
A University of Toronto study discovered a new communication pathway between the gut and lung, highlighting the role of a little-known protozoan in shaping immune responses. The study found that this microbe can worsen airway inflammation in allergic asthma but provide protection against respiratory infections.
A new study estimates that India will see over 62.4 million cases of tuberculosis in the next two decades, posing a significant burden on the country's health and economy. Scaling up existing treatment regimens could generate at least $28 billion in GDP gains, highlighting the need for increased investment in TB control measures.
Researchers identified five fungi species with toxic effects against the bacterium, which disrupts cellular levels of thiols essential for bacterial survival. The findings support a strategy for developing treatment-shortening drugs by targeting biological processes maintaining thiol levels.
World health leaders outlined policy recommendations to tackle TB among refugee and migrant populations, leveraging successful experiences from regional countries. The report's ten strategies aim to guide stakeholders worldwide in achieving TB elimination for all.
Researchers at Tufts University discovered that TB bacteria maintain a consistent growth rate throughout their life cycle, defying expectations. The study also reveals new growth behaviors of TB bacteria, including the ability to grow from either end after division.
Researchers identified a genetic weakness in drug-resistant Mycobacterium tuberculosis, allowing them to develop targeted drugs. This technology has the potential to combat other drug-resistant pathogens and prevent their spread.
Researchers have uncovered why a relatively new antibiotic for tuberculosis works against multidrug-resistant strains by identifying deficiencies in a critical enzyme. This discovery could lead to improved treatments and drug development strategies, potentially allowing for lower doses or shorter treatment times.
A research team led by Dr. Bernd Meibohm is working on developing new treatments for tuberculosis that require fewer pills, shorter treatment periods, and reduce the risk of resistance. They aim to replace linezolid with Spectinamide 1810, a safer alternative that can be administered directly to the lungs.
A new study published in The Lancet Child & Adolescent Health found that children living in areas with a high burden of tuberculosis have a consistently high annual risk of developing TB infection throughout childhood. By age 10, over 10% of children developed TB disease.
Researchers discovered that tuberculosis alters liver metabolism and can push patients towards metabolic disease like diabetes. The study suggests undiagnosed TB could be a significant contributor to metabolic health issues.
Researchers at Texas Biomedical Research Institute developed a human cell culture model of alveolar macrophages, which helped make a key finding about the role of tumor necrosis factor (TNF) in tuberculosis (TB). The study found that TNF is critical to protect against TB but not other infectious diseases.
A new study has discovered a novel semi-synthetic compound derived from natural compounds that exhibits potent activity against Mycobacterium tuberculosis, including multi-drug resistant strains. The compound, BPD-9, provides a promising chemical scaffold for developing new anti-tuberculosis drugs.
African wormwood, a plant used for centuries to treat various illnesses, contains a compound that can kill the bacteria causing tuberculosis. Researchers have identified this compound, an O-methylflavone, as effective against both active and inactive states of the mycobacterium.
Researchers at Texas Biomedical Institute have developed a TB therapy that does not interfere with combined antiretroviral therapy (cART) in patients with HIV. The host-directed therapy blocks an immune system protein and has shown improved control of TB when used with antibiotics.
After analyzing human immune cells and TB patients, researchers found that TCA metabolism plays a crucial role in DNA methylation. Adding an inhibitor of TCA activation reduced detrimental marks, suggesting epigenetic healing is possible. This discovery may lead to new treatment strategies for infectious diseases.
A recent study found that racial and ethnic tuberculosis (TB) disparities among US-born persons can result in significant long-term health consequences. The research indicates that these disparities can have substantial effects on the economy as well, potentially affecting TB elimination goals within the US.
Researchers identified a genetic cause of TNF deficiency, which incapacitates a specific immune process in the lungs, leading to targeted and severe illness. This finding may upend long-held assumptions about the immune system and have far-reaching clinical implications.
A subset of CD4 T cells create an anti-inflammatory environment within the lung tissue, protecting against TB reinfection by limiting bacterial growth and disease severity. The discovery complements previous research on protective immune T cells in controlling TB infection, suggesting a potential key to improving existing vaccines.
Researchers discovered a non-virulent bacterium, Mycobacterium spongiae, that shares 80% of its genetic material with M. tuberculosis, shedding light on the disease's origins. The study provides valuable insights into the evolution and virulence of TB.
A study analyzing 5.5 million EU/EEA infectious disease cases over 10 years found significant sex differences in notified male versus female cases for several diseases. The proportion of males ranged from 40-45% for pertussis and Shiga toxin-producing Escherichia coli infections to 75-80% for HIV/AIDS.
Researchers found that macrophages induce cancer cell apoptosis and then eat away dead cells after BCG vaccine injection in a new animal model. This breakthrough could lead to more effective bladder cancer treatments.
A new study by UC Davis researchers found that male gender and residency in large towns are the strongest risk factors for active TB progression in South Africa. Higher socioeconomic status, age, and migration history also impact active TB risk.
Researchers found that close household contacts of people diagnosed with geographically restricted TB strains had a lower rate of infection and active TB disease compared to those exposed to widespread lineages. This suggests a shared evolution between humans and microbes, amplifying the risk for infection.
Researchers have identified a group of molecules called callyaerins that can act against tuberculosis by targeting a specific membrane protein of the bacterium Mycobacterium tuberculosis. These substances inhibit bacterial growth without affecting human cells, offering a promising new approach to treating the disease.
Human lung organoids can form lifelike models for tuberculosis infection, enabling the testing of anti-tuberculosis drugs. These models may also facilitate the development of host-directed therapies.
Scientists from Hackensack Meridian Health have identified a new potential pathway for developing vaccines against tuberculosis by targeting marginal zone B (MZB) cells, a natural response to TB infection. The discovery suggests that boosting MZB cell activity could provide reliable and durable protection against the disease.